Exobiosphere is a Luxembourg-based space biotechnology company pioneering high-throughput drug discovery in microgravity. Its mission is to extend and improve life both on Earth and in space by using the unique conditions of microgravity to accelerate biomedical research and unlock therapies that are difficult or impossible to develop under Earthās gravity.
At the heart of Exobiosphereās work is its Orbital High-Throughput Screening (OHTS) platform, a fully automated, space-ready laboratory capable of conducting thousands of biological experiments in orbit. This enables more physiologically relevant disease models and rapid insights into drug efficacy, target identification and disease phenotyping. By integrating space-grade lab automation, advanced analytics and real-time data transfer, Exobiosphere helps pharmaceutical, biotech and healthcare partners to shorten research timelines and improve success rates in drug development.
Founded in 2024 and headquartered in Luxembourgās House of BioHealth, Exobiosphere aims to make space a routine and essential part of the biomedical research and development pipeline, partnering with global space and life science organisations to expand the frontiers of medicine and space health.